Clinical Trials
579 trialsFORBES
Sun Yat-sen University
BEACON
University of Birmingham
GFPC 06-2018
Centre Francois Baclesse
ATHENA
Centre Leon Berard
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
Samsung Medical Center
BEATcc
Grupo Español de Investigación en Cáncer de Ovario
A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.
National Taiwan University Hospital
AMBITION
Japanese Foundation for Cancer Research
EndoBARR
Medical College of Wisconsin
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
ANGIO-TAX+
Centre Oscar Lambret
TRIPLET
Federation Francophone de Cancerologie Digestive
Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Tianjin Medical University Cancer Institute and Hospital
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
VASCATAQ
University Hospital, Rouen
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CHA University
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
Sun Yat-sen University
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
COMBATBIL
University Hospital, Essen
HCC
CHA University
Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer
Sun Yat-sen University
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Rigshospitalet, Denmark
SAMCO
Federation Francophone de Cancerologie Digestive
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
City of Hope Medical Center
BRIGHT
Tongji Hospital
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Thomas Jefferson University
FMT in IT-refractory HCC - FAB-HCC Pilot Study
Medical University of Vienna
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Ohio State University Comprehensive Cancer Center
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
Peking University
NIVACOR
Gruppo Oncologico Italiano di Ricerca Clinica
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
CLASSIC5
Hunan Province Tumor Hospital
Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer
Al-Mustansiriyah University
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Ohio State University Comprehensive Cancer Center
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
University of Utah
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Dana-Farber Cancer Institute
ATALANTE
ARCAGY/ GINECO GROUP
CAIRO5
Dutch Colorectal Cancer Group
ITACa
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stanford University
Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer
Vejle Hospital